ARCA Biopharma Receives Notice Of Allowance For Patent For Treating Heart Failure Patients With Bucindolol Based On Genetic Testing

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued. Once issued, the patent will provide coverage for methods of treating heart failure patients with bucindolol based on genetic testing.


"We are very pleased with the USPTO's decision to grant this patent which extends our pharmacogenetic intellectual property protection around bucindolol in to 2025," said Michael R. Bristow, President and Chief Executive Officer of ARCA. "This allowance and anticipated issuance of the patent highlight ARCA's belief in, and commitment to, developing genetically targeted therapies for the treatment of heart failure and other cardiovascular diseases."


About GencaroTM


GencaroTM (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro is well-tolerated in patients with advanced HF.


Source

ARCA biopharma